https://www.selleckchem.com/products/a-674563.html
26%) of 114 subjects, with no change for 54 (47.37%) of 114 subjects. Grade 1 adverse events were observed in 26 of 114 subjects (nausea, headache, back pain, diarrhea); one grade 2 (petechiae) and one grade 3 (abdominal pain) adverse event were observed. No grade 2 or 3 adverse events were related to study drug and none required intervention. Imaging with Ga-DOTATOC PET-CT has a significant impact on management of patients with neuroendocrine tumors. Imaging with Ga-DOTATOC PET-CT has a significant impact on management of patients wit